Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Sthanu Subramanian: Dabigatran and Mechanical Heart Valves
Sthanu Subramanian/LinkedIn
Jun 27, 2026, 18:16

Sthanu Subramanian: Dabigatran and Mechanical Heart Valves

Sthanu Subramanian, Pediatrician, shared a post on X about a recent article by Noel C. Chan et al. published in Arteriosclerosis, Thrombosis, and Vascular Biology, adding:

“Dabigatran and Mechanical heart valves.

Dabigatran (Pradaxa) is contraindicated for mechanical heart valves because it is significantly less effective at preventing blood clots on artificial valves and carries a higher risk of major bleeding compared to traditional treatments like Warfarin.

The danger of using dabigatran in these patients was proven by the RE-ALIGN Trial, which was stopped early due to severe safety risks.

The specific reasons for this include:

1. Higher Rates of Valve Thrombosis:

Dabigatran only targets one specific clotting factor (thrombin).

Mechanical valves are highly prone to clot formation, and warfarin’s broader mechanism of action is much more effective at preventing clots from building up on the artificial material.

2. Increased Risk of Strokes:

Because dabigatran fails to adequately prevent clots from forming on the valves, users experienced more strokes and systemic embolisms.

3. Excessive Bleeding:

The drug also led to a significantly higher rate of major bleeding events, including dangerous bleeding in the pericardial space surrounding the heart.

4. Absorption Issues:

Dabigatran has very low oral bioavailability and can cause topical anticoagulant effects in the gastrointestinal tract, contributing to higher bleeding risks.

Mechanisms of mechanical heart valve thrombosis and the differential effects of anticoagulants on thrombin generation.”

Title: Anticoagulation for Mechanical Heart Valves: Will Oral Factor Xa Inhibitors Be Effective?

Authors: Noel C. Chan, Jeffrey I. Weitz, John W. Eikelboom

Sthanu Subramanian

Other posts featuring Sthanu Subramanian on Hemostasis Today.

Anticoagulation bleeding Blood Clot Formation dabigatran Factor Xa Factor Xa Inhibitors Health Hematology Hemostasis Hemostasis News Hemostasis Today Jeffrey I. Weitz John W. Eikelboom Mechanical Heart Valves Medicine Noel C. Chan Pradaxa Sthanu Subramanian stroke Thrombin thrombosis Warfarin
NewsFeed